Aimmune Therapeutics
Latest round
- Series B
Last raised
- Jan 2015
Total raised
- $97M
Investors
- 7
About Aimmune Therapeutics
Aimmune Therapeutics Inc.Founded in 2011 in Brisbane, US, Aimmune Therapeutics develops therapies for food allergies. The company pioneered its flagship product, Palforzia, which was released after extensive clinical trials.00 mn. The company has completed 5 deals since inception.Aimmune Therapeutics specializes in developing treatments for food allergies, with Palforzia as its primary product. This oral immunotherapy aims to desensitize individuals to peanuts, significantly decreasing the likelihood of allergic reactions. It is mainly targeted at children and adolescents aged 4 to 17 years but is also applicable to adults.In 2019, Aimmune Therapeutics reported an EBITDA of USD -247,349,000, primarily deriving revenue from sales of Palforzia.Aimmune Therapeutics plans to introduce new products and expand its market presence, particularly focusing on international markets such as Europe and Canada.00 mn which will support these initiatives.00 mn during its IPO in August 2015, positioning it well for future growth.
Who invested in Aimmune Therapeutics
7 investors across 2 rounds
See all investors in Aimmune Therapeutics
Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.
Questions about Aimmune Therapeutics
Who invested in Aimmune Therapeutics?
Aimmune Therapeutics has 7 investors on record across 2 venture rounds. Sign up free to see every VC on the cap table and the rounds they joined.
How much funding has Aimmune Therapeutics raised?
Aimmune Therapeutics has raised 2 venture rounds. Sign up free to see how much each round raised and the total.
When did Aimmune Therapeutics last raise money?
Aimmune Therapeutics's most recent round on record is a Series B, in Jan 2015.
What does Aimmune Therapeutics do?
Aimmune Therapeutics is a biotechnology company.
Where is Aimmune Therapeutics headquartered?
Aimmune Therapeutics is headquartered in Brisbane, US.
Which VCs invest in companies like Aimmune Therapeutics?
Among active investors with capital left to deploy, Andreessen Horowitz, Founders Fund, Accel and Thrive Capital back biotechnology companies at Aimmune Therapeutics's stage. Their profiles are linked below.
VCs backing biotechnology startups at Series B
Raising like Aimmune Therapeutics? Find the right VCs.
Capital Atlas matches your startup to active investors by stage, sector and region.